Neoprobe presses on with lymphatic tracer
This article was originally published in Clinica
Executive Summary
Neoprobe says it is on track to begin early next year multicentre studies of its lymphatic-tracing agent for detecting potentially cancerous lymph nodes for tumours. Its announcement follows the release of promising preclinical and clinical results for the product, called Lymphoseek, which is designed for use in sentinel node biopsy procedures.